Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak, który się rozprzestrzenił lub nie można go usunąć operacyjnie i który nie zareagował na standardowe leczenie (w tym 5-FU lub kapecytabinę).
- •Pacjenci z rakiem jelita grubego mogą zostać poproszeni o wykonanie biopsji przed rozpoczęciem leczenia.
- •Rak, który można zmierzyć w badaniach obrazowych.
- •Wiek powyżej 18 lat.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (odpowiadający ocenie 0-2 w skali ECOG).
- •Dostępna tkanka guza z poprzednich badań do analizy molekularnej.
- •Zakończenie wcześniejszego leczenia systemowego co najmniej 2 tygodnie lub 5 okresów półtrwania leku przed rozpoczęciem badania.
- •Prawidłowe wyniki badań krwi (liczba neutrofilów, płytki krwi) i parametrów wątrobowych oraz nerkowych.
✗ Disqualifies
- •Pacjenci poniżej 18 roku życia.
- •Pacjenci z chorobami współistniejącymi, które mogą wpływać na bezpieczeństwo lub skuteczność leczenia (niektóre choroby wątroby, nerek).
- •Pacjenci z aktywnym zakażeniem wirusem zapalenia wątroby typu B, które nie jest kontrolowane.
- •Pacjenci, którzy stosowali inne leki mogące wchodzić w interakcje z lekami badanymi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (22)
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
UF Health Cancer Institute - Gainesville
Gainesville, United States
Memorial Hospital East
Shiloh, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, United States
Montefiore Medical Center-Einstein Campus
The Bronx, United States
Montefiore Medical Center-Weiler Hospital
The Bronx, United States
Montefiore Medical Center - Moses Campus
The Bronx, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
Vanderbilt Breast Center at One Hundred Oaks
Nashville, United States
Vanderbilt University/Ingram Cancer Center
Nashville, United States
Trial contact
Site Public Contact
Fa-Chyi Lee
PRINCIPAL_INVESTIGATOR
Site Public Contact
Thomas J. George
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joaquina C. Baranda
PRINCIPAL_INVESTIGATOR
Site Public Contact
Chaoyuan Kuang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Davendra P. Sohal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Susanna V. Ulahannan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Anwaar Saeed
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.